AGILENT TECHNOLOGIES, INC.(A)— Stock Profile, AI Score & Financials
Technology · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
AGILENT TECHNOLOGIES, INC. (A) stock profile, AI quality score, and SEC EDGAR financial data, a Technology sector company. 13F Pro's AI-powered ranking engine scores A at 67.1/100 on a 32-signal composite quality model, placing it at rank #378 of 2,961 stocks — the top 25% of the AI-ranked universe. A scores in the top quartile across balance sheet strength (87.4), revenue scale (83.1), profitability (80.6). Shareholder dilution risk is elevated at 41.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), AGILENT TECHNOLOGIES, INC. reports quarterly revenue of $1.9B, net income of $362.0M, an operating margin of 23.6%. Top institutional holders of A by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. A trades on the NYSE exchange and files with the SEC under CIK 1090872. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate A daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AGILENT TECHNOLOGIES, INC. directly from SEC EDGAR.
AI Quality Score
67.1/100
AI Rank
#378
Revenue
$1.9B
Net Income
$362.0M
Free Cash Flow
$439.0M
Operating Margin
23.6%
A key financials by period
AGILENT TECHNOLOGIES, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$6.9B
$1.3B
21.3%
FY 2024
10-K
$6.5B
$1.3B
22.9%
FY 2023
10-K
$6.8B
$1.2B
19.8%
FY 2022
10-K
$6.8B
$1.3B
23.6%
FY 2021
10-K
$6.3B
$1.2B
21.3%
FY 2020
10-K
$5.3B
$719.0M
15.8%
Institutions holding A
Institutional investors reporting a position in AGILENT TECHNOLOGIES, INC. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-09-01 — Q3 FY2026 (quarter ended July 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Agilent reported Q3 revenue of $1.88B (+8% YoY) with net income of $362M, while acquiring Biocare for $950M to expand its pathology portfolio.
Biggest Revenue Drivers
Agilent CrossLab$786M+6% YoY
Services and consumables portfolio; strong growth in repair, maintenance, compliance services and consumables businesses across pharmaceutical and chemical markets.
Life Sciences and Diagnostics Markets$746M+11% YoY
Strong revenue growth from liquid chromatography, Agilent Advanced Therapeutics, consumables and genomics businesses; includes Biocare acquisition contribution.
Biggest Revenue Drivers
Total revenue: $1,878M+8% YoY
Agilent CrossLab$786M+6% YoY
Services and consumables portfolio; strong growth in repair, maintenance, compliance services and consumables businesses across pharmaceutical and chemical markets.
Life Sciences and Diagnostics Markets$746M+11% YoY
Strong revenue growth from liquid chromatography, Agilent Advanced Therapeutics, consumables and genomics businesses; includes Biocare acquisition contribution.
Applied Markets$346M+7% YoY
Strong growth in chemical and advanced materials market driven by spectroscopy, gas chromatography, remarketed instruments and vacuum businesses.
Largest Expense Items
Cost of products and services$836M-1% YoY
Higher sales volume and tariff refunds offset by wage increases and higher variable pay.
Selling, general and administrative$475M+14% YoY
Higher costs from transformational initiatives, variable pay, wage increases and unfavorable currency impact.
Research and development$123M+10% YoY
Higher costs from transformational initiatives, wage increases and higher variable pay partially offset by restructuring savings.
Margins: Gross margin improved 4 percentage points to 55.5%, driven by higher sales volume, net tariff refunds, price increases and favorable mix, partially offset by wage and variable pay increases. Operating margin expanded 3 percentage points to 23.6%, benefiting from gross margin expansion and lower restructuring costs despite higher transformational initiative expenses.
Watch Items from the Filing
Biocare acquisition on June 24, 2026 for $950M net cash consideration adds $549M goodwill and $520M intangible assets, representing material integration risk and synergy execution dependency.
Tariff situation remains dynamic with only de minimis net benefit (~1 ppt margin lift) from IEEPA refunds; future refund timing and approval uncertain pending legal and regulatory developments.
Inventory days on hand increased to 120 days from 107 days YoY due to strategic tariff mitigation purchases, tying up $110M in cash flow YTD.
FY26 and FY25 restructuring plans total $124M cumulative expense with expected annual savings of $120M–$130M once completed; execution risk on realizing full benefit.
Academic and government market revenue declined; this end-market showed weakness across Life Sciences and Agilent CrossLab segments despite overall company growth.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
